灭活SARS-CoV-2疫苗在有无既往感染的医护人员中均产生高抗体应答
研究纳入330名接种两剂CoronaVac(间隔28天)的医护人员,检测抗Spike/RBD IgG。无既往感染组首剂后14天抗体阳性率48.2%,第二剂后28天99.2%;有既往感染组首剂后阳性率100%,两组差异显著。全程两剂后总阳性率99.4%。作者认为既往感染者第二剂无显著获益,单剂接种可能足够。
要点
- 无既往感染者首剂后14天抗体阳性率48.2%,第二剂后28天升至99.2%。
- 有既往感染者首剂后抗体阳性率100%,显著高于无感染组的48.2%。
- 全程两剂后总抗体阳性率99.4%,高血压者抗体滴度显著较低。
核心结论
- 两剂CoronaVac在医护人员中产生有效体液免疫,有既往COVID-19史者抗体应答显著高于无感染史组。
- 鉴于第二剂无显著获益,作者认为对有既往COVID-19史者单剂接种可能足够,但需监测体液和细胞免疫并考虑新变异株以验证此方法。
研究设计与样本
- 研究纳入330名在伊斯坦布尔大学-Cerrahpaşa医学院医院工作并接种两剂灭活CoronaVac(Sinovac Life Sciences,中国)SARS-CoV-2疫苗(间隔28天)的医护人员。
- 于第一剂后14天和第二剂后28天检测抗Spike/RBD IgG水平,采用化学发光微粒子免疫分析法(CMIA)(ARCHITECT IgG II Quant test,Abbott,美国),该方法与蚀斑减少中和试验(PRNT)100%一致。
主要发现
- 参与者中女性211人(63.9%),男性119人(36.1%),平均年龄39.6±7.7岁。
- 无既往COVID-19史者(n=255)第一剂后14天抗体阳性率为48.2%(95%CI:42.1-54.3),第二剂后28天为99.2%(95%CI:98.1-100)。
- 高血压患者抗体滴度显著较低(p=0.011)。
- 有既往COVID-19史者(n=75)第一剂后抗体阳性率与无感染史组比较为100% vs 48.2%(p=0.000),第二剂后抗Spike/RBD抗体水平(以≥1050 AU/mL滴度相当于PRNT 1/80稀释)为25.9% vs 54.7%(p=0.000),有感染史组显著高于无感染史组。
- 全部研究组两剂接种后抗体阳性率为99.4%(95%CI:98.6-100)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Healthcare workers (HCWs) were among the first groups to be vaccinated in Turkey. The data to be obtained by the vaccination of HCWs would guide wide spread vaccination programs. MATERIALS AND METHODS: The study included 330 HCWs working at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike /RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. Chemiluminescent microparticle immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test (PRNT), was used. RESULTS: Of the participants, 211 (63.9%) were female, 119 (36.1%) were male, and mean age was 39.6 ± 7.7 years. In those without prior COVID-19 history; (n = 255) antibody positivity was detected as 48.2% (95% CI: 42.1-54.3) 14 days after the first dose of vaccine, and 99.2% (95% CI: 98.1-100) at day 28 after the second dose. Antibody titers were significantly lower in patients with hypertension (p = 0.011). In those with prior history of COVID-19 (n = 75); both the antibody positivity rates after the first vaccine (48.2% vs 100%, p = 0.000) and the anti-spike/RBD antibody levels after the second vaccine (with a ≥ 1050 AU/mL titer equivalent to PRNT 1/80 dilution) was significant than infection-naive group (25.9% vs. 54.7%, p = 0.000). Antibody positivity after two doses of vaccination for all study group was 99.4% (95% CI: 98.6-100). CONCLUSIONS: Two doses CoronaVac produce effective humoral immunity in HCWs. Antibody response is significantly higher in those with prior history of COVID-19 than infection-naive group. Given no significant benefit of the second dose, a single shot of vaccination may be sufficient for those with prior history of COVID-19. Monitoring humoral and cellular immune responses, considering new variants, is required to validate this approach.
引用
- Dinc HO, Saltoglu N, Can G, et al. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine. 2021. PMID: 34839992. doi:10.1016/j.vaccine.2021.11.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。